Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.

PloS one - 1 Jan 2013

Antonysamy Stephen, Condon Bradley, Druzina Zhanna, Bonanno Jeffrey B, Gheyi Tarun, Zhang Feiyu, MacEwan Iain, Zhang Aiping, Ashok Sheela, Rodgers Logan, Russell Marijane, Gately Luz John

Abstract excerpt

The enhancer-of-zeste homolog 2 (EZH2) gene product is an 87 kDa polycomb group (PcG) protein containing a C-terminal methyltransferase SET domain. EZH2, along with binding partners, i.e., EED and SUZ12, upon which it is dependent for activity forms the core of the polycomb repressive complex 2 (PRC2). PRC2 regulates gene silencing by catalyzing the methylation of histone H3 at lysine 27. Both overexpression and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalytic Domain
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease

Share to Enhancer of Zeste Homolog 2 Protein

Share to Models, Molecular

Share to Polycomb Repressive Complex 2

Share to Sf9 Cells

Share to Spodoptera

Source

Open in PubMed Open full text

Identifiers

PMID: 24367637
DOI: 10.1371/journal.pone.0084147
PMCID: PMC3868555

Genes

SET
EED
SUZ12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.PMID 24367637Read ↗

Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.Semantic proximity Read ↗

Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.Semantic proximity Read ↗

The conserved N-terminal SANT1-binding domain (SBD) of EZH2 Regulates PRC2 ActivitySemantic proximity Read ↗

The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity.Semantic proximity Read ↗

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.Semantic proximity Read ↗

Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.Semantic proximity Read ↗

Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Semantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

Dominant alleles identify SET domain residues required for histone methyltransferase of Polycomb repressive complex 2.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2.Semantic proximity Read ↗

Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.